Low-dose 7-day transdermal buprenorphine in daily clinical practice – perceptions of elderly patients with moderate non-malignant chronic pain

References

• Langley PC. The prevalence, correlates and treatment of pain in the European Union. Curr Med Res Opin 2011;27:463-80
   PubMed Web of Science ®Google Scholar
• Langley P, Müller-Schwefe G, Nicolaou A, et al. The societal impact of pain in the European Union: health-related quality of life and healthcare resource utilization. J Med Econ 2010;13:571-81
   PubMedGoogle Scholar
• Langley P, Müller-Schwefe G, Nicolaou A, et al. The impact of pain on labor force participation, absenteeism and presenteeism in the European Union. J Med Econ 2010;13:662-72
   PubMedGoogle Scholar
• Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10:287-333
   PubMed Web of Science ®Google Scholar
• Reid KJ, Harker J, Bala MM, et al. Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. Curr Med Res Opin 2011;27:449-62
   PubMed Web of Science ®Google Scholar
• Jakobsson U. The epidemiology of chronic pain in a general population: results of a survey in southern Sweden. Scand J Rheumatol 2010;39:421-9
   PubMed Web of Science ®Google Scholar
• Frießem CH, Willweber-Strumpf A, Zenz MW. Chronic pain in primary care. German figures from 1991 and 2006. BMC Health 2009;9:299
   PubMed Web of Science ®Google Scholar
• Vadivelu N, Hines RL. Management of chronic pain in the elderly: focus on transdermal buprenorphine. Clin Interv Aging 2008;3:421-30
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
   PubMed Web of Science ®Google Scholar
• Kaestli L-Z, Wasilewski-Rasca A-F, Bonnabry P, et al. Use of transdermal drug formulations in the elderly. Drugs Aging 2008;25:269-80
   PubMed Web of Science ®Google Scholar
• Reidenberg B, Eltahtawy A, Munera C, et al. Daily pharmacokinetic performance of a buprenorphine transdermal system (BTDS) for up to 7 days. J Clin Pharmacol 2001;41:1027 (abstract 57)
   Google Scholar
• Electronic Medicines Compendium. Transtec 35, 52.5 and 70 micrograms transdermal patch. Available at: http://www.medicines.org.uk/emc/medicine/8864/SPC/Transtec+35,+52.5+and+70+micrograms++transdermal+patch [Last accessed 20 March 2012]
   Google Scholar
• World Health Organization. Cancer pain ladder. Available at: http://www.who.int/cancer/palliative/painladder/en/ [Last accessed 20 March 2012]
   Google Scholar
• Breivik H, Ljosaa TM, Stengaard-Pedersen K, et al. A 6-months, randomized, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naïve to potent opioids. Scand J Pain 2010;1:122-41
   PubMedGoogle Scholar
• Sittl R, Nuijten M, Nautrup BP. Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany. Clin Ther 2006;28:1144-54
   PubMed Web of Science ®Google Scholar
• Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009;13:219-30
   PubMed Web of Science ®Google Scholar
• Pergolizzi J, Aloisi AM, Dahan A, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract 2010;10:428-50
   PubMed Web of Science ®Google Scholar
• Plosker GL. Buprenorphine 5, 10 and 20 µg/h transdermal patch. A review of its use in the management of chronic non-malignant pain. Drugs 2011;71:2491-509
   PubMed Web of Science ®Google Scholar
• Steiner DJ, Sitar S, Wen W, et al. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. J Pain Symptom Manage 2011;42:903-17
   PubMed Web of Science ®Google Scholar
• Spyker DA, Hale ME, Lederman M, et al. Long-term use of buprenorphine transdermal system (BTDS) in patients with chronic pain. J Am Geriatr Soc 2002;50(4 Suppl):S66(abstract)
   Web of Science ®Google Scholar
• Schutter U, Ritzdorf I, Heckes B. Treatment of chronic osteoarthritis pain: effectivity and safety of a 7 day matrix patch with a low dose buprenorphine (in German). MMW Fortschr Med 2008;150:96-103
   PubMedGoogle Scholar
• Schutter U, Ritzdorf I, Heckes B. The transdermal 7-day buprenorphine patch – an effective and safe treatment option, if tramadol or tilidate/naloxone is insufficient. Results of a non-interventional study (in German). MMW Fortschr Med 2010;152:62-9
   PubMedGoogle Scholar
• Nagel B, Gerbershagen HU, Lindena G, et al. Development and evaluation of the multidimensional German pain questionnaire. Schmerz 2002;16:263-70 (in German)
   PubMed Web of Science ®Google Scholar
• Müller-Schwefe G, Zenz M (eds). The German Pain Questionnaire. German Pain Association, 2006. ISBN: 3-00-017-440-0 (in German)
   Google Scholar
• Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70
   PubMed Web of Science ®Google Scholar
• Tait RC, Chibnall JT, Krause S. The pain disability index: psychometric properties. Pain 1990;40:171-82
   PubMed Web of Science ®Google Scholar
• Müller-Schwefe GHH, Überall MA. Pain and quality of life. Gesundh ökon Qual manag 2011;16:S20-2 (in German)
   Google Scholar
• Weber J, Schley M, Casutt M, et al. Tetrahydrocannabinol (delta 9-THC) treatment in chronic central neuropathic pain and fibromyalgia patients: results of a multicenter survey. Anesthesiol Res Pract 2009;preprint827290
   Google Scholar
• Schmitt N, Gerbershagen HU. The Mainz Staging System (MPSS) for chronic pain. Pain 1990;41(Suppl 5):S484 (abstract)
   Google Scholar
• Schilling A, Corey R, Leonard M, et al. Acetaminophen: old drug, new warnings. Cleve Clin J Med 2010;77:19-27
   PubMed Web of Science ®Google Scholar
• Ofman J, MacLean CH, Straus WL, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol 2002;29:804-12
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;331:1310-16
   PubMed Web of Science ®Google Scholar
• Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Opinion of the committee for medicinal products for human use pursuant to article 5(3) of regulation (EC) no 726/2004, for nonselective non steroidal anti-inflammatory drugs (NSAIDs). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/01/WC500054342.pdf [Last accessed 20 March 2012]
   Google Scholar
• American Geriatrics Society. Pharmacological management of persistent pain in older persons. JAGS 2009;57:1331-46
   PubMed Web of Science ®Google Scholar
• Varrassi G, Müller-Schwefe G, Pergolizzi J, et al. Pharmacological treatment of chronic pain – the need for change. Curr Med Res Opin 2010;26:1231-45
   PubMed Web of Science ®Google Scholar
• Veldhuijzen DS, Greenspan JD, Smith MT. Sleep and quality of life in chronic pain. In: Verster JS, et al Sleep and Quality of Life in Clinical Medicine. Totowa, NJ, USA: Humana Press, 2008:187-97
   Google Scholar
• Broekmans S, Dobbels F, Milisen K, et al. Medication adherence in patients with chronic non-malignant pain: is there a problem? Eur J Pain 2009;13:115-23
   PubMed Web of Science ®Google Scholar
• Richter A, Anton SF, Koch P, . The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307-35
   PubMed Web of Science ®Google Scholar
• Gallagher AM, Leighton-Scott J, van Staa TP. Utilization characteristics and treatment persistence in patients prescribed low-dose buprenorphine patches in primary care in the United Kingdom: a retrospective cohort study. Clin Ther 2009;31:1707-15
   PubMed Web of Science ®Google Scholar
• Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther 2005;7:R1046-51
   PubMed Web of Science ®Google Scholar
• Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010;1:CD006605
   PubMed Web of Science ®Google Scholar
• Sorgatz H, Reinecke H. Long-term use of opioids for noncancer pain (LONTS). In German. Available at: http://www.awmf.org/uploads/tx_szleitlinien/041-003l.pdf [Last accessed 9 August 2012]
   Google Scholar